Nurix Therapeutics, Inc. (NRIX)

CIK 0001549595 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-07-09) · 99.1
Q1-2026 8-K (2026-04-08) · 99.1
Latest FY-2025 8-K (2026-01-28) · 99.1
Q3-2025 8-K (2025-10-09) · 99.1
Q2-2025 8-K (2025-07-09) · 99.1
Q1-2025 8-K (2025-04-08) · 99.1
FY-2024 8-K (2025-01-28) · 99.1  |  8-K (2025-01-13) · 99.1 · 99.2
Q3-2024 8-K (2024-10-11) · 99.1
Q2-2024 8-K (2024-07-11) · 99.1
Q1-2024 8-K (2024-04-10) · 99.1
FY-2023 8-K (2024-02-15) · 99.1
Q3-2023 8-K (2023-10-12) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Balance Sheets
Balance Sheets (P)
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Statements of Operations
Consolidated Statements of Operations
Statements of Comprehensive Loss
Consolidated Statements of Comprehensive Loss
Statements of Stockholders' Equity
Consolidated Statements of Stockholders' Equity
Statements of Cash Flows
Consolidated Statements of Stockholders' Equity (P)
Statements of Stockholders' Equity (P)
Consolidated Statements of Cash Flows
Notes
Balance Sheet Components
Collaboration Agreements
Commitments and Contingencies
Common Stock
Consolidated Balance Sheet Components
Cybersecurity Risk Management and Strategy Disclosure
—
Defined Contribution Plan
Fair Value Measurements
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Net Loss Per Share
Organization
Pay Vs Performance Disclosure
Related Party Transactions
Segment Information
Stock-based Compensation
Subsequent Events
Summary of Significant Accounting Policies